Grant: CIHR - ICR / Cancer Research Society Partnership - Res. Grants - Breast Cancer
University of Saskatchewan
$62,500.00
225Ac-labeled anti-nectin-4 radioimmunoconjugate with/without immune checkpoint blockage in triple negative breast cancer.
FY 2022-23
Summary
Triple negative breast cancer (TNBC) isthe most aggressive breast cancer with a 5-year survival rate of 11% for patients with distant metastasis. Keytruda an immunotherapy (ICI) approved in combination with chemotherapy against TNBC with modest benefits. Nectin-4 is overexpressed in 60-70% of TNBC. This work will focus on developing new therapeutic actinium-225 radiolabeled antibody conjugate (radioimmunoconjugate RIC) against nectin-4 positive TNBC. Thistherapeutic will be tested in cells, and in mouse models. We will investigate if thisradiolabeled antibody can stimulate tumor and immune cells, and take advantage of this by combining it with ICI(s) for enhanced efficacy. This RIC could improve survival of TNBC patientsif translated.
Department
Program
CIHR - ICR / Cancer Research Society Partnership - Res. Grants - Breast Cancer
Recipient
Location
Saskatchewan, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
488261
Name
Fonge Humphrey A
Region
Saskatchewan
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Cancer Research Society Inc.; Cancer Research Society Inc.
Instname2
Cancer Research
Prcname2
Special Cases
Projecttitle
225Ac-labeled anti-nectin-4 radioimmunoconjugate with/without immune checkpoint blockage in triple negative breast cancer.
Programtype2
Operating Grants
Orgnameinp2
University of Saskatchewan
Cihramount2
$62,500
Cihrequipment2
$0
Programname2
CIHR - ICR / Cancer Research Society Partnership - Res. Grants - Breast Cancer
Keyworddelim
Chemotherapy And Radiotherapy; Imaging Technologies; Immunotherapy
Abstract
Triple negative breast cancer (TNBC) isthe most aggressive breast cancer with a 5-year survival rate of 11% for patients with distant metastasis. Keytruda an immunotherapy (ICI) approved in combination with chemotherapy against TNBC with modest benefits. Nectin-4 is overexpressed in 60-70% of TNBC. This work will focus on developing new therapeutic actinium-225 radiolabeled antibody conjugate (radioimmunoconjugate RIC) against nectin-4 positive TNBC. Thistherapeutic will be tested in cells, and in mouse models. We will investigate if thisradiolabeled antibody can stimulate tumor and immune cells, and take advantage of this by combining it with ICI(s) for enhanced efficacy. This RIC could improve survival of TNBC patientsif translated.
Competitiondate
202302
Approvedterm2
1 yr 0 mth
Pinamesdelim
Fonge, Humphrey A
Approvedterm
1 an 0 mois
Cihrcontribution2
ICR~ $62,500~ $0~
